Johnson & Johnson $JNJ Shares Bought by Northside Capital Management LLC

Key Points

• Northside Capital Management LLC significantly increased its stakes in Johnson & Johnson by 830.8% in Q2, acquiring an additional 29,819 shares, bringing its total holdings to 33,408 shares worth over $5 million.
• A number of analysts have raised their price targets for Johnson & Johnson, with Citigroup and JPMorgan both setting their targets at $200.00 and Royal Bank of Canada at $185.00, indicating positive market sentiment.
• Johnson & Johnson reported strong quarterly earnings, with a revenue increase of 5.8% year-over-year and earnings per share of $2.77, surpassing analysts' expectations.

Northside Capital Management LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 830.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 33,408 shares of the company's stock after acquiring an additional 29,819 shares during the quarter. Northside Capital Management LLC's holdings in Johnson & Johnson were worth $5,103,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock valued at $38,800,371,000 after buying an additional 1,170,120 shares in the last quarter. Northern Trust Corp increased its position in shares of Johnson & Johnson by 0.4% in the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock valued at $5,131,723,000 after buying an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Johnson & Johnson by 3.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock valued at $3,133,602,000 after buying an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Johnson & Johnson by 2.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after buying an additional 448,666 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Citigroup lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Royal Bank Of Canada lifted their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $181.40.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Up 0.0%

JNJ opened at $176.62 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market capitalization of $425.35 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 2.25 and a beta of 0.40. The business has a 50-day moving average of $173.80 and a two-hundred day moving average of $161.90. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.